Sanofi (NASDAQ:SNY) Earns Neutral Rating from Analysts at The Goldman Sachs Group

The Goldman Sachs Group initiated coverage on shares of Sanofi (NASDAQ:SNY) in a report published on Friday, Marketbeat reports. The brokerage issued a neutral rating and a $65.00 price target on the stock.

Several other analysts also recently issued reports on the company. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Three analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Sanofi presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.50.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $56.90 on Friday. Sanofi has a twelve month low of $45.22 and a twelve month high of $60.12. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $144.40 billion, a price-to-earnings ratio of 22.85, a PEG ratio of 1.01 and a beta of 0.58. The firm has a 50-day moving average of $54.55 and a two-hundred day moving average of $52.85.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sanofi

A number of large investors have recently made changes to their positions in the business. Synergy Asset Management LLC acquired a new position in Sanofi in the fourth quarter worth approximately $25,000. McClarren Financial Advisors Inc. increased its holdings in Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after buying an additional 543 shares during the last quarter. Lee Danner & Bass Inc. acquired a new position in Sanofi in the fourth quarter worth approximately $31,000. Bessemer Group Inc. increased its holdings in Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock worth $32,000 after buying an additional 242 shares during the last quarter. Finally, Sunbelt Securities Inc. increased its holdings in Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after buying an additional 313 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.